France's Erytech Closer To Realizing Market Ambitions With Eryaspase US Filing
Positive FDA Feedback For Leukemia Submission
Executive Summary
It has taken almost two decades but it looks as though Erytech could get approval for eryaspase in the US in two indications next year – acute lymphoblastic leukemia and pancreatic cancer.
You may also be interested in...
Erytech’s Solid Tumor Hopes Falter As Eryaspase Fails In Phase III Pancreatic Cancer Trial
Erytech’s eryaspase has failed in its Phase III TRYbeCA-1 trial for second-line pancreatic cancer despite analyst excitement for the solid tumor indication. Its attentions now turn, once again, to its acute lymphoblastic leukemia indication.
Erytech Pulls Graspa ALL Filing To Focus On Pancreatic Cancer
The French biotech's shares have sunk 30% but Erytech's decision to withdraw its European marketing authorization application for Graspa in the crowded acute lymphoblastic leukemia market, and focus solely on solid tumors, has gone down well with analysts.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.